Genmab - ADR

NASDAQ:GMAB 4:00:00 PM EDT

21.46

+0.06 (+0.28%)

5:16:14 PM EDT: $22.09 +0.63 (+2.94%)

Market Cap (Intraday)	13.20B
Current PE	12.03
Forward PE	14.03
2yr Forward PE	11.86

See more stats

Estimates Current Quarter

Revenue	$911.82 Million
Adjusted EPS	$0.40

See more estimates

10-Day MA	$21.23
50-Day MA	$21.05
200-Day MA	$21.30

See more pivots

Genmab - ADR Stock, NASDAQ:GMAB

Carl Jacobsens Vej 30, Valby, Copenhagen, Central Denmark 2500

Denmark

Phone: +45.70.20.27.28

Number of Employees: 2682

http://www.genmab.com

Description

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.